消化

订阅

MedSci主页 / 所有栏目 / 消化

Cell Rep：科学家阐明治疗结直肠癌的新靶点

2016-01-05 佚名 生物谷

结直肠癌靶点STING信号
关注

图片来源：www.oncology-central.com 近日，一项刊登在国际杂志Cell Reports上的研究论文中，来自迈阿密大学米勒医学院的研究人员通过对结直肠癌进行研究，报道了机体免疫反应对肿瘤产生反应的关键性研究发现，这项研究也首次详细地解释了干扰素基因刺激子(STING，stimulator of interferon genes)信号通路如何扮演重要的角色来改变机体对细胞转

图片来源：www.oncology-central.com

近日，一项刊登在国际杂志Cell Reports上的研究论文中，来自迈阿密大学米勒医学院的研究人员通过对结直肠癌进行研究，报道了机体免疫反应对肿瘤产生反应的关键性研究发现，这项研究也首次详细地解释了干扰素基因刺激子(STING，stimulator of interferon genes)信号通路如何扮演重要的角色来改变机体对细胞转化的免疫反应。

研究者Barber说道，我们都知道STING对于抗病毒及抗菌反应非常重要，但截止到目前为止，我们并不清楚STING在人类肿瘤中的功能，本文研究中我们次揭示了STING信号在结直肠癌和其它癌症中处于被抑制的状态，而这种事件或许会促进细胞转化进而躲避免疫系统的监视。

结直肠癌每年在美国会影响大约120万人的健康，而且每年都会有15万人被诊断为结直肠癌，而这种癌症也是在男性和女性中的第三大常见的癌症，大部分的结肠癌会以良性息肉形式发生，如果早期诊断的话就可以成功治疗，然而如果肿瘤发生扩散，那么患者的生存率就会急剧下降。

利用结直肠癌动物疾病模型进行研究，研究人员发现，STING信号的缺失可以负向影响机体识别DNA损伤细胞的能力，尤其是特殊的细胞因子—对细胞信号非常重要的小型蛋白，可以促进组织损伤修复，以及启动免疫系统抗肿瘤的效应并不足以产生足够的免疫反应来清除结直肠癌细胞。研究者说道，我们发现受损的STING信号可以促进损伤细胞来躲避机体免疫系统的监视，而且如果机体不能够识别并且攻击癌细胞，那么癌细胞就会增殖最终扩散到机体其它部位中。

研究者表示，评估STING信号可以作为一种治疗结直肠癌及其它类型癌症的预后标志物，比如，本文研究表明有缺陷的STING信号或许容易被用作癌症疗法的溶瘤病毒所攻击，而随后的研究中研究者还发现，STING信号的激活子是抗肿瘤免疫反应的潜在刺激子，总的来讲，STING信号的控制或许对于癌症发生及开发相应疗法非常重要。

原始出处：

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869278, encodeId=46ef18692e82d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 19 01:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959534, encodeId=52fe195953467, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 11 00:11:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288162, encodeId=2d641288162e4, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452780, encodeId=c70c1452e809d, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52404, encodeId=cc9f5240496, content=好东西，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Jan 06 13:30:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-11-19 zhaozhouchifen

    #Cell#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1869278, encodeId=46ef18692e82d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 19 01:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959534, encodeId=52fe195953467, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 11 00:11:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288162, encodeId=2d641288162e4, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452780, encodeId=c70c1452e809d, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52404, encodeId=cc9f5240496, content=好东西，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Jan 06 13:30:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-11 维他命

    #CEL#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1869278, encodeId=46ef18692e82d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 19 01:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959534, encodeId=52fe195953467, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 11 00:11:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288162, encodeId=2d641288162e4, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452780, encodeId=c70c1452e809d, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52404, encodeId=cc9f5240496, content=好东西，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Jan 06 13:30:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-07 lsndxfj

    #新靶点#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1869278, encodeId=46ef18692e82d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 19 01:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959534, encodeId=52fe195953467, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 11 00:11:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288162, encodeId=2d641288162e4, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452780, encodeId=c70c1452e809d, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52404, encodeId=cc9f5240496, content=好东西，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Jan 06 13:30:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-07 crystal0564

    #结直肠#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869278, encodeId=46ef18692e82d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Nov 19 01:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959534, encodeId=52fe195953467, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Jan 11 00:11:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288162, encodeId=2d641288162e4, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452780, encodeId=c70c1452e809d, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jan 07 00:11:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52404, encodeId=cc9f5240496, content=好东西，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Jan 06 13:30:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-06 andruhn

    好东西，学习了！

    0

相关资讯

Lancet：宣传方式对结直肠癌筛查的影响大有不同！

英国结直肠癌筛查项目因社会经济状态不同存在差异，研究者进行了一项研究，评估备选4种干预方案能否减少这种差异，改善筛查有益健康。该研究纳入了60-74岁所有具有筛查资格的人群。每组试验均是标准信息与标准信息基础上添加干预的比较：干预1（2012年11月），总结关键信息要点的补充传单；干预2（2012年3月），描述参与者故事的叙述传单；干预3（2013年6月），医师通过邀请函支持该项目；干预4（201

《中国结直肠癌诊疗规范（2015版）》发布

“《中国结直肠癌诊疗规范（2015版）》（以下简称《规范》）的出版，对于基层肿瘤医疗来说是非常及时的，也是非常重要的。”近日，来自北京市大兴区医院的医生韩磊在《规范》新闻发布会上告诉记者。 然而，尽管第一版《规范》已推行5年，但与会专家均认为，我国结直肠癌诊疗的全国同质化尚待时日。 据全国肿瘤防治研究办公室教授陈万青介绍，结直肠癌在中国的发病率居肿瘤类第三位，去年新发病例31万人、死亡15万人

JCO：结直肠癌患者的认知障碍机制仍不明确

曾有研究报道，癌症患者存在认知功能障碍。因此,本研究纵向评估了结直肠癌(CRC)和健康对照组（HC）的认知功能。 参与者在试验基线期完成了在第6个月、12个月和24个月的认知评估和认知系统、疲劳情况、生活治疗及焦虑/抑郁的调查问卷报告。血液测试包括细胞因子、凝血因子、载脂蛋白E基因型和性激素。以患者第12个月的总体认知功能作为研究主要终点。 研究人员收纳了289名局部CRC患者，其中，173名

Am J Clin Nutr：黄酮类不能降低结直肠癌风险

黄酮类化合物体外抑制结肠癌细胞的生长。对息肉预防试验进行二次分析表明,更高的黄酮醇摄入,在统计学上显著降低晚期腺瘤复发的风险。先前的前瞻性研究关于结直肠癌评估，只有有限数量的黄酮类子类和摄入量范围,且产生不一致的结果。研究者进行了一项研究，探究习惯性摄入更高剂量黄酮类化合物（黄酮醇、黄酮、黄烷酮、黄烷醇和花青素）能否降低结直肠癌风险。该研究纳入了42,478名男性和76,364名女性，使用经验证的

PLoS ONE ：膳食豆制品或异黄酮摄入可降低患结直肠癌的风险

总豆制品或膳食异黄酮摄入量较高与整体结直肠癌的风险降低有关,尤其能降低受试者患远端结肠癌或直肠癌的风险。

BMC Cancer：不想患结直肠癌？多吃含钙物质！

摄入高剂量的饮食钙被认为具有预防直肠癌的作用，研究者对日常饮食钙摄入非常低的韩国人进行了一项病例对照研究，探究饮食钙摄入和结直肠癌风险间的剂量反应关系。该研究纳入了2010年8月-2013年8月诊断为结直肠癌的患者，同时纳入对照组。通过半定量食物频度问卷调查采集参与者饮食钙摄入情况，并根据癌症位置将其分为结肠癌、远端结肠癌和直肠癌。使用二元和多分类回归分析模型评估饮食钙摄入量和结直肠癌风险间联系。